250 related articles for article (PubMed ID: 2864278)
1. Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
Thierfelder S; Cobbold S; Kummer U; Waldmann H; Schuh R
Exp Hematol; 1985 Oct; 13(9):948-55. PubMed ID: 2864278
[TBL] [Abstract][Full Text] [Related]
2. Antilymphocytic antibodies and marrow transplantation. IX. T-cell depletion in marrow donors with C1q high and low affinity antibodies for suppression of GVHD in fully mismatched mice.
Antica M; Hoffmann-Fezer G; Thierfelder S
Exp Hematol; 1989 Oct; 17(9):942-7. PubMed ID: 2570711
[TBL] [Abstract][Full Text] [Related]
3. Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodies.
Kummer U; Thierfelder S; Mysliwietz J
Eur J Immunol; 1990 Jan; 20(1):107-12. PubMed ID: 1968387
[TBL] [Abstract][Full Text] [Related]
4. Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies.
Mysliwietz J; Thierfelder S; Hoffmann-Fezer G; Kummer U
Transplantation; 1990 Apr; 49(4):749-55. PubMed ID: 1970200
[TBL] [Abstract][Full Text] [Related]
5. In vivo immunosuppression by pan-T cell antibodies relates to their isotype and to their C1q uptake.
Kummer U; Thierfelder S; Hoffmann-Fezer G; Schuh R
J Immunol; 1987 Jun; 138(12):4069-74. PubMed ID: 2884259
[TBL] [Abstract][Full Text] [Related]
6. Effects of restoring lethally irradiated mice with anti-Thy 1.2-treated bone marrow: graft-vs-host, host-vs-graft, and mitogen reactivity.
Norin AJ; Emeson EE
J Immunol; 1978 Mar; 120(3):754-8. PubMed ID: 24664
[TBL] [Abstract][Full Text] [Related]
7. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
Cobbold SP; Hale G; Clark MR; Waldmann H
Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
[TBL] [Abstract][Full Text] [Related]
8. Antilymphocytic antibodies and marrow transplantation. VIII. Recipient conditioning with Clq-affine monoclonal anti-pan T antibodies prevents GVHD in homozygous fully mismatched mice.
Thierfelder S; Kummer U; Schuh R; Mysliwietz J
Blood; 1986 Oct; 68(4):818-24. PubMed ID: 2875752
[TBL] [Abstract][Full Text] [Related]
9. Antilymphocytic antibodies and marrow transplantation. XIV. Antibody-induced suppression of graft-versus-host disease in C3-decomplemented mice differentiates two T-cell-depletion pathways.
Thierfelder S; Mysliwietz J; Hoffmann-Fezer G; Kummer U
Blood; 1991 May; 77(10):2285-91. PubMed ID: 2029584
[TBL] [Abstract][Full Text] [Related]
10. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
11. Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T cell monoclonal antibody to the allograft recipients.
Knulst AC; Bril-Bazuin C; Benner R
Eur J Immunol; 1991 Jan; 21(1):103-7. PubMed ID: 1671355
[TBL] [Abstract][Full Text] [Related]
12. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
Herve P
J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
[TBL] [Abstract][Full Text] [Related]
14. Antilymphocytic antibodies and marrow transplantation. V. Suppression of secondary disease by host-versus-theta-graft reaction.
Thierfelder S; Rodt H
Transplantation; 1977 Jan; 23(1):87-92. PubMed ID: 319574
[TBL] [Abstract][Full Text] [Related]
15. Mouse skin graft prolongation with donor strain bone marrow and anti-lymphocyte serum: surface markers of the active bone marrow cells.
De Fazio S; Hartner WC; Monaco AP; Gozzo JJ
J Immunol; 1985 Nov; 135(5):3034-8. PubMed ID: 2864375
[TBL] [Abstract][Full Text] [Related]
16. New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
Slavin S; Or R; Naparstek E; Cividalli G; Weshler Z; Weiss L; Mumcuoglu M; Engelhard D; Aker M; Pollack A
Isr J Med Sci; 1986; 22(3-4):264-7. PubMed ID: 3528046
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease using antibody to Thy 1. A role for complement in vivo.
Hamilton BL; Harris D
Transplantation; 1985 Jul; 40(1):90-6. PubMed ID: 2861676
[TBL] [Abstract][Full Text] [Related]
18. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences.
Korngold R; Sprent J
J Immunol; 1985 Nov; 135(5):3004-10. PubMed ID: 3876371
[TBL] [Abstract][Full Text] [Related]
19. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
20. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
Mysliwietz J; Thierfelder S
Blood; 1992 Nov; 80(10):2661-7. PubMed ID: 1358260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
